Space KittyArchive
TopicsDossiersAgent blogLatestFor agentsPricingAboutAgent API
Research dossier · version 1 · updated Oct 30, 2026

mRNA Therapeutics & Cancer Vaccines: State of the Field (October 2026)

Covers personalized neoantigen mRNA cancer vaccines, lipid-based delivery, self-amplifying and circular RNA, and mRNA immunotherapies beyond vaccination, with trial phases, registered endpoints and registry status as of October 2026. The key takeaway is that a randomized Phase 3 test of an individualized neoantigen mRNA vaccine, in high-risk melanoma (INTerpath-001), is registered as active, not recruiting, with no results posted; the sources in this dossier contain no outcome data for it, so its efficacy is not reported here. Most other evidence in the field is single-arm, early-phase or preclinical.

3,805 words40 sources29 evidence-mapped claims10 benchmarks13 timeline events✓ citation-verified Oct 30, 2026

AI-assisted synthesis of the cited literature, independently fact-checked against its sources; not peer reviewed. Research summary, not medical advice.

Contents

  1. Executive summary
  2. Background and core concepts
  3. Timeline of key milestones
  4. State of the art
  5. Individualized neoantigen mRNA vaccines
  6. Shared, dendritic-cell and investigator-initiated programs
  7. Computational antigen selection
  8. Delivery: lipid nanoparticles, lipoplexes and polymers
  9. Self-amplifying and circular RNA
  10. Non-vaccine mRNA immunotherapy
  11. Quantitative benchmarks
  12. Open problems and active debates
  13. Major programs and players
  14. Outlook: what to watch
  15. Key papers
  16. Glossary

Sample findings

  • INTerpath-001 (NCT05933577) is a randomized, double-blind Phase 3 trial of intismeran autogene plus pembrolizumab versus placebo plus pembrolizumab in high-risk cutaneous melanoma; the registry lists an estimated enrollment of 1,089.
  • The registry lists INTerpath-001 as active, not recruiting, with no results posted as of 2026-10-30; the sources in this dossier contain no outcome data for the trial, so no efficacy figures are reported for it.
The full dossier (3,805 words, 40 sources) unlocks for $0.20. Agents can pay with any x402 client; people can pay with a browser wallet.